CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate

Journal of Infectious Diseases

Volumn 212, Issue 10, 2015, Pages 1618-1628

  Chu, Haiyan ^a   George, Sarah L ^b,c   Stinchcomb, Dan T ^a   Osorio, Jorge E ^a   Partidos, Charalambos D ^a  

^a Takeda Vaccines   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD8+ T cells; Cytokines; Dengue virus; Multifunctional T cells; Vaccine

Indexed keywords

DENGUE VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LIVE ATTENUATED TETRAVALENT DENGUE VACCINE; LIVE VACCINE; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; RECOMBINANT VACCINE; VIRUS ANTIGEN;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; FLAVIVIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNIZATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROTYPE; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS GENOME; VOLUNTEER; BIOSYNTHESIS; COHORT ANALYSIS; IMMUNOLOGY; NORMAL HUMAN; PROCEDURES; VACCINATION;

ADULT; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CYTOKINES; DENGUE VACCINES; DENGUE VIRUS; HEALTHY VOLUNTEERS; HUMANS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84952638965     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv258     Document Type: Article

References (36)

1. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva, Switzerland, 2009.
2. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8(12 suppl):S7-16.
3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
4. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29:7221-8.
5. Endy TP. Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol 2014; 5:183.
6. Sabin AB. The dengue group of viruses and its family relationships. Bacteriol Rev 1950; 14:225-32.
7. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67.
8. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010; 10:712-22.
9. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008; 225:300-13.
10. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518-28.
11. Butrapet S, Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5'noncoding region and nonstructural proteins 1 and 3. J Virol 2000; 74:3011-9.
12. Huang CY-H, Butrapet S, Pierro DJ, et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000; 74:3020-8.
13. Huang CY-H, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003; 77:11436-447.
14. Kinney RM, Butrapet S, Chang GJ, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997; 230:300-8.
15. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011; 29:7251-60.
16. Brewoo JN, Kinney RM, Powell TD, et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 2012; 30:1513-20.
17. Osorio JE, Brewoo JN, Silengo SJ, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011; 84:978-87.
18. Ambuel Y, Young G, Brewoo JN, et al. A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates. Front Immunol 2014; 5:263.
19. Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) administered to flavivirus-naive healthy adults in Colombia: a randomized, placebo-controlled Phase 1 study. Lancet of Infect Dis 2014; 14:830-8.
20. George SL, Wong MA, Dube TJ, et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naïve adults: a randomized, double-blind phase I clinical trial. J Infect Dis 2015; 212:1032-41.
21. DejnirattisaiW, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8.
22. de Alwis R, Beltramello M, Messer WB, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLOS Negl Trop Dis 2011; 5:e1188.
23. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271-83.
24. Weiskopf D, Sette A. T cell immunity to infection with dengue virus in humans. Front Immunol 2014; 5:93.
25. Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26:5712-21.
26. Lindow JC, Borochoff-Porte N, Durbin AP, et al. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLOS Negl Trop Dis 2012; 6: e1742.
27. Yauch LE, Zellweger RM, Kotturi MF, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182:4865-73.
28. Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 2013; 110:E2046-53.
29. Gunther VJ, Putnak R, Eckels KH, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011; 29:3895-904.
30. Duangchinda T, DejnirattisaiW, Vasanawathana S, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010; 107:16922-7.
31. Matusan AE, Kelley PG, Pryor MJ, Whisstock JC, Davidson AD, Wright PJ. Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus. Gen Virol 2001; 82:1647-56.
32. Matusan AE, Pryor MJ, Davidson AD, Wright PJ. Mutagenesis of the dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication. J Virol 2001; 75: 9633-43.
33. Piazza P, Campbell D, Marques E, et al. Dengue virus infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol 2014; 177:696-702.
34. Weiskopf D, Angelo MA, Bangs DJ, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 2014; 88:11383-94.
35. Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009; 183:7919-30.
36. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-9.